Last update 07 Mar 2025
Excelmab, Inc.

Excelmab, Inc.

Private Company|
2016|
Guangdong Sheng, China
|
10-50
|
www.excelmab.com

Overview

Basic Info

Introduction
ExcelMab is a biopharmaceutical developer of bispecial antibodies, focusing on the research and development of tumor immunity bispecial antibodies. Through the bispecial antibody platform independently developed and built, ASMED uses antibody genetic engineering construction technology to develop therapeutic bispecial antibody drugs for tumor diseases, providing new solutions for the field of tumor therapy. A number of dual antibody products have been developed to cover breast cancer, gastric cancer, chronic lymphocytic leukemia and other indications.

Tags

Neoplasms
Digestive System Disorders
Hemic and Lymphatic Diseases
Bispecific T-cell Engager (BiTE)
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms9
Hemic and Lymphatic Diseases1
Immune System Diseases1
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Bispecific T-cell Engager (BiTE)8
Monoclonal antibody1
Top 5 TargetCount
CD3 x MUC172
CD3 x HER21
CD3 x DLL31
CD3 x GPC31
CD20 x CD31

Related

9
Drugs associated with Excelmab, Inc.
EX-103
Target
CD20 x CD3
Mechanism
CD20 inhibitors [+1]
Active Org.
Excelmab, Inc.Excelmab, Inc.
Originator Org.
Excelmab, Inc.Excelmab, Inc.
Active Indication
CD20 positive Non-Hodgkin Lymphoma [+2]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
EX-101
Target
CD3 x HER2
Mechanism
CD3 stimulants [+1]
Active Org.
Excelmab, Inc.Excelmab, Inc.
Originator Org.
Excelmab, Inc.Excelmab, Inc.
Active Indication
Breast Cancer [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
EX-105
Target
CD276 x CD3
Mechanism
CD276 inhibitors [+1]
Active Org.
Excelmab, Inc.Excelmab, Inc.
Originator Org.
Excelmab, Inc.Excelmab, Inc.
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhaseIND Approval
First Approval Ctry. / Loc.-
First Approval Date-
3
Clinical Trials associated with Excelmab, Inc.
CTR20212292
/ RecruitingPhase 1
一项开放性、剂量递增和剂量扩展评估EX101注射液治疗HER2阳性晚期实体瘤患者的I期临床研究
[Translation] An open-label, dose-escalation and dose-expansion phase I clinical study evaluating EX101 injection in patients with HER2-positive advanced solid tumors
NCT06021678
/ RecruitingPhase 1/2
A Phase I/II Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
CTR20212096
/ RecruitingPhase 1/2
一项评价EX103注射液在复发或难治CD20阳性非霍奇金淋巴瘤患者中的有效性、安全性、耐受性和药代动力学特征的I/II期临床研究
[Translation] A Phase I/II clinical study to evaluate the efficacy, safety, tolerability and pharmacokinetic characteristics of EX103 injection in patients with relapsed or refractory CD20-positive non-Hodgkin's lymphoma
100 Clinical Results associated with Excelmab, Inc.
Login to view more data
0 Patents (Medical) associated with Excelmab, Inc.
Login to view more data
100 Deals associated with Excelmab, Inc.
Login to view more data
100 Translational Medicine associated with Excelmab, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
4
Preclinical
IND Approval
1
1
Phase 1
Phase 2
1
5
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
EX-101
 ( CD3 x HER2 )		Stomach Cancer
More
Phase 1
EX-103
 ( CD20 x CD3 )		Chronic Lymphocytic Leukemia
More
Phase 1
EX-108
 ( CD3 x Trop-2 )		Stomach Cancer
More
Preclinical
EX-105
 ( CD276 x CD3 )		Pancreatic Cancer
More
Preclinical
CM-110
 ( CD3 x DLL3 )		Small Cell Lung Cancer
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free